.: OKULISTYKA :.

Wydanie 3/2013
str. 46

Zastosowanie VEGF Trap-Eye w leczeniu obrzęku plamki w przebiegu zakrzepu żyły środkowej siatkówki – wyniki wieloośrodkowych badań klinicznych COPERNICUS i GALILEO

VEGF Trap-Eye Application in the Treatment of Macular Edema Following Central Retinal Vein Occlusion – Results of the COPERNICUS and GALILEO Multicentre Clinical Trials

Robert Rejdak^1,2, Magdalena Futyma-Ziaja², Małgorzata Szkaradek², Aneta Lewicka-Chomont², Michael Koss³

¹Klinika Okulistyki Ogólnej Katedry Okulistyki Uniwersytetu Medycznego w Lublinie
Kierownik: prof. dr hab. n. med. Robert Rejdak
²Oddział Okulistyki Wojewódzkiego Szpitala Specjalistycznego im. F. Chopina w Rzeszowie
Kierownik: lek. Aneta Lewicka-Chomont
³ Klinika Okulistyki Uniwersytetu Goethego, Frankfurt nad Menem, Niemcy
Kierownik: prof. dr hab. n. med. Frank Koch

Summary: Macular edema following central retinal vein occlusion is a common cause of visual loss. The therapy regimen of this condition has undergone significant modifications in recent years. Aflibercept (VEGF Trap-Eye, Eylea) is a new drug from the vascular endothelial growth factor inhibitors group. Previous trials proved its efficacy in the neovascular form of Age-related Macular Degeneration, and in diabetic macular edema. Currently, there are available results of two similar trials, COPERNICUS and GALILEO, which were to assess the efficacy and safety of aflibercept in patients suffering from macular edema following central retinal vein occlusion. The results unequivocally indicate high therapeutic efficacy of the drug in this clinical indication. In both trials, a gain of 15-letters or more was observed in over 56 per cent of patients who were given aflibercept compared with 12% and 22% in the control group, respectively.

Słowa kluczowe: obrzęk plamki, zakrzep żyły środkowej siatkówki, VEGF Trap-Eye, GALILEO, COPERNICUS.

Keywords: macular edema, central retinal vein occlusion, VEGF Trap-Eye, aflibercept, GALILEO, COPERNICUS.

powrót